

IN THE CLAIMS:

Please amend claims 11-15 to read as follows:

11. (Amended) The method of claim 10 wherein the gastric or intestinal diseases or disorders involve lesions.
12. (Amended) A medicament for treatment of gastric or intestinal diseases or disorders comprising the micro-organism of claim 1.
13. (Amended) The medicament of claim 12 for treatment of acute gastro-intestinal inflammatory diseases comprising acute colitis, acute flare-ups of Crohn's diseases or ulcerative colitis.
14. (Amended) The medicament of claim 12 for treatment of chronic and spontaneously recurring diseases of the gastro-intestinal tract comprising Crohn's disease (enteritis regionalis) or ulcerative colitis (colitis ulcerosa).
15. (Amended) The medicament of claim 12 for inhibiting the formation of lesions caused by gastric or intestinal diseases or disorders.

REMARKS

The specification has been amended to note the claim to priority and to add reference to an earlier filed PCT application as required under 37 C.F.R. § 1.78(a)(2). Also attached is an Abstract on a new page. The Abstract attached hereto is the same Abstract as found on the coversheet of the WO 01/02570 publication.

In this amendment, claim 11 is amended to be dependent from claim 10 and claims 12-15 are amended to read as product claims rather than "use" claims. These amendments are made to